Abstract
This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12–24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000 PFU, Group B) or 1 dose of VARILRIX™, (∼40,000 PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer⩾5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
